Skip to the main content.
Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

1 min read

Advancing Dose Escalation Strategies with Bayesian Modeling

Learn how our biostatistics and strategic consulting teams collaborated with our biotechnology sponsor to advance dose escalation strategies through Bayesian modeling in a Phase 1/2 study for a novel oncology compound. Our efforts led to real-time, data-driven decision making and reduced trial duration while maintaining patient safety.

A biotechnology sponsor developing an oncology therapy engaged us to support the design and execution of a multicenter, open-label Phase 1/2 dose escalation and expansion study. The sponsor aimed to shorten traditional dose escalation timelines without compromising patient safety, moving beyond conventional 3+3 design limitations.

In this case study, learn how Veristat experts were able to work with the sponsor to solve challenges across:

  • Bayesian CRM implementation

  • Real-time decision support

  • Operational complexity management

  • Safety review committee participation

  • Multi-cycle DLT integration

  • Strategic consultative planning

Download our complete case study "Advancing Dose Escalation Strategies with Bayesian Modeling"

DOWNLOAD

 
Contact us today to learn how we can help:
LET'S TALK
Positioning a Sponsor’s First Trial for Success: A Comprehensive Planning Approach for Cancer Antibody

Positioning a Sponsor’s First Trial for Success: A Comprehensive Planning Approach for Cancer Antibody

Discover how Veristat's strategic expertise transformed a clinical-stage biotech company's first Phase I trial. Download the case study for insights...

Read More
Advancing Oncology Innovation with Adaptive Trial Designs

Advancing Oncology Innovation with Adaptive Trial Designs

Learn how Veristat’s strategic and regulatory expertise helped guide a complex, multi-regional Phase 3 oncology study with balanced global enrollment...

Read More
Targeted Indication Selection Using Simon 2-Stage Design

Targeted Indication Selection Using Simon 2-Stage Design

Learn how Veristat’s biostatistics and strategic consulting teams helped a biotech sponsor prioritize oncology indications through efficient,...

Read More